Abstract 733P
Background
Patients (pts) with advanced EC who progress on or after platinum (PT)-based chemotherapy (chemo) and immunotherapy (IO) have poor prognosis. SG is a Trop-2–directed antibody-drug conjugate that demonstrated encouraging efficacy and manageable safety in pts with metastatic, relapsed/refractory EC (Santin A et al; J Clin Oncol, 2023). We report updated results from TROPiCS-03.
Methods
This is a multicohort, open-label, phase 2 basket study in pts with metastatic solid tumors. Pts in the EC cohort had progressed after prior PT-based chemo and IO. Pts received SG 10 mg/kg on days 1 and 8 of a 21-day cycle. Primary end point was objective response rate (ORR) by investigator assessment per RECIST 1.1. Key secondary end points included clinical benefit rate (CBR), duration of response (DOR), progression-free survival (PFS) per investigator assessment; overall survival (OS); safety.
Results
At data snapshot (March 8, 2024), this study enrolled 41 pts, with a median follow-up of 19.4 mo (range, 14.4-30.3). Median age was 68 years (range, 44-83), 20% of pts were microsatellite instability high, median prior lines of therapy was 3 (range, 1-6). ORR was 27% (95% CI, 14-43); median DOR was 9.0 mo (95% CI, 2.8-NR); median OS was 15.0 mo (95% CI, 5.9-NR) (table). Pts who previously received both PT-based chemo and IO (85%, n=35) had similar outcomes as the overall cohort. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 85% pts, most commonly neutropenia (49%), diarrhea (22%), and anemia (20%). Discontinuation rate due to TEAEs was 7%. Three pts had TEAEs leading to death (1, due to unknown cause, was deemed related to SG by the investigator).
Conclusions
In this first report of OS and with longer follow-up, SG shows promising clinical activity, with durable responses in pts pretreated with PT-based chemo with or without IO for advanced/metastatic EC. The safety profile was manageable, with low treatment discontinuation due to TEAEs. Table: 733P
Summary of efficacy endpoints
All Patients (n = 41) | |
ORR (confirmed CR + PR), n (%) [95% CI] | 11 (27) [14-43] |
Best overall response, n (%) | |
Confirmed CR | 1 (2) |
Confirmed PR | 10 (24) |
SD | 17 (42) |
Progressive disease | 8 (20) |
Not evaluable | 1 (2) |
Not assessed a | 4 (10) |
Clinical benefit rate (confirmed CR + PR + SD duration ≥ 6 months b), n (%) [95% CI] | 17 (42) [26-58] |
Median DOR c [95% CI], months | 9.0 [2.8-NR] |
Median PFS [95% CI], months | 5.0 [2.8-9.8] |
Median OS [95% CI], months | 15.0 [5.9-NR] |
aPts without any post-baseline assessments are counted as not assessed.
bDuration ≥ 6 months for SD only.
cBased on patients who achieved a confirmed CR or PR. CR, complete response; NR, not reached; PR, partial response; SD, stable disease.
Clinical trial identification
NCT03964727.
Editorial acknowledgement
Medical writing and editorial support was provided by Priya Talluri, of Parexel.
Legal entity responsible for the study
Gilead Sciences, Inc.
Funding
Gilead Sciences, Inc.
Disclosure
B.R. Corr: Financial Interests, Institutional, Advisory Board: GSK, Gilead, ImmunoGen, Zentalis, Merck, Corcept, ImVax; Financial Interests, Institutional, Invited Speaker: Targeted Oncology; Financial Interests, Institutional, Coordinating PI: ImmunoGen, Clovis. E.E. Dumbrava: Financial Interests, Institutional, Other, Research/grant funding: Bayer HealthCare Pharmaceuticals, Immunocore Ltd, Amgen, Aileron Therapeutics, Compugen Ltd, Gilead, BOLT Therapeutics, Aprea Therapeutics, Bellicum, PMV Pharma, Triumvira, Seagen Inc, Mereo BioPharma 5 Inc, Sanofi, Rain Oncology, Astex Therapeutics, Sotio, Mersana Therapeutics, Poseida, Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: PMV Pharma; Financial Interests, Personal, Advisory Board: BOLT Therapeutics, Mersana Therapeutics, Orum Therapeutics, Summit Therapeutics. A.I. Spira: Financial Interests, Personal, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines; Financial Interests, Personal, Other, Consulting or Advisory Role / Honoraria: Amgen, Novartis, Takeda, AstraZeneca/MedImmune, Merck, Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria: CytomX Therapeutics, Janssen Oncology, Bayer; Financial Interests, Institutional, Officer, CEO: Next Oncology Virginia; Financial Interests, Personal, Stocks/Shares: Eli Lilly; Financial Interests, Institutional, Local PI: LAM Therapeutics, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, AbbVie, Ignyta, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol Myers Squibb, Loxo, Arch Therapeutics, Gritstone, Plexxikon, Amgen, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, Rubius, Synthekine, Mersana, Blueprint Medicines, Kezar, Revolution Med. L. Willmott: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Eisai, ImmunoGen, Merck, Seagen. J.E. Butrynski: Financial Interests, Personal, Other, Consultant as part of Ontada and US Oncology in Real World Experience in Dedifferentiated Liposarcoma: Boehringer Ingelheim; Financial Interests, Personal, Full or part-time Employment, Principal Investigator for Real World Experience in Dedifferentiated Liposarcoma at US Oncology: Ontada; Financial Interests, Institutional, Coordinating PI, National Principal investigator for US Oncology for trial of Sacituzumab Govitecan: Gilead. K.Y. Tse: Financial Interests, Personal, Invited Speaker: Zai Lab, GSK; Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca; Financial Interests, Institutional, Research Grant: Pfizer, Zai Lab, AstraZeneca; Financial Interests, Institutional, Coordinating PI: WKK Medical Equipment Co. Ltd. (Hong Kong); Financial Interests, Institutional, Local PI: Gilead; Non-Financial Interests, Leadership Role: Asia and Oceania Federation of Obstetrics and Gynecology Oncology committee. J. Patel: Financial Interests, Personal, Stocks/Shares: Gilead Sciences, Inc.. S. Mekan: Financial Interests, Institutional, Full or part-time Employment: Gilead Sciences. S. Mocci: Financial Interests, Personal, Full or part-time Employment, I am a full employee of the Company: Gilead. T. Wu: Financial Interests, Personal, Full or part-time Employment: Gilead Sciences, Inc; Financial Interests, Personal, Stocks or ownership: Gilead Sciences, Inc. A.D. Santin: Financial Interests, Personal, Advisory Board: Merck, Eisai, Daiichi Sankyo, R-Pharm-US; Financial Interests, Institutional, Local PI: Merck, Verastem; Non-Financial Interests, Advisory Role: Merck, Eisai, Daiichi Sankyo, R-Pharm-USA.
Resources from the same session
651P - Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors
Presenter: Jinming Yu
Session: Poster session 01
652P - BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Presenter: Oscar Reig Torras
Session: Poster session 01
653P - A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Presenter: Matthew Chau Hsien Ng
Session: Poster session 01
654P - Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Presenter: Bernard Doger de Spéville
Session: Poster session 01
655P - Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK
Presenter: Rachel Woodford
Session: Poster session 01
656P - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Victor Moreno Garcia
Session: Poster session 01
657P - Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Presenter: Noé Herbel
Session: Poster session 01
658P - First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Cátia Fava Gaspar
Session: Poster session 01
659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Presenter: Zev Wainberg
Session: Poster session 01
660P - Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Presenter: Laura Mansi
Session: Poster session 01